Please note that this product was withdrawn from the Community register of designated orphan medicinal products in May 2014 on request of the sponsor.
On 24 January 2006, orphan designation (EU/3/05/345) was granted by the European Commission to Généthon, France, for lentiviral vector containing the human Wiskott Aldrich syndrome protein gene for the treatment of Wiskott Aldrich syndrome.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
- What is Wiskott Aldrich syndrome?
A chromosome is an organised structure of DNA (the genetic material) and protein that is found in cells of the body. In humans, the so-called X and Y-chromosomes determine the sex, but carry also other genetic information. Wiskott Aldrich syndrome is caused by an abnormality of a gene located on the X chromosome. This gene is responsible for the production of a protein, Wiskott Aldrich protein, which is part of the structure responsible for the cellular “scaffolding” enabling the shape and movement of the cells (cytoskeleton). The cytoskeleton is also fundamental for the cell to be able to capture substances or organisms (endocytosis) or for actions linked to the body’s defense system. This means that patients suffering from Wiskott Aldrich syndrome have different symptoms, depending on the cells affected, such as decrease in the number of platelets and increased bleeding, eczema, repeated infections, or increased risk for development of autoimmune diseases and tumours.
Wiskott Aldrich syndrome is chronically debilitating and life-threatening.
- What is the estimated number of patients affected by the condition?
At the time of designation, Wiskott Aldrich Syndrome affected approximately 0.01 in 10,000 people in the European Union (EU). This was equivalent to a total of around 500 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 25), Norway, Iceland and Liechtenstein. At the time of designation, this represented a population of 468,900,000 (Eurostat 2006).
- What treatments are available?
No satisfactory methods exist that were authorised at the time of application. For a minority of patients (those at a very young age and having a compatible donor) bone marrow transplant is a therapeutic option. Medicines generally available for the complications of the disease are used in these situations.
- How is this medicine expected to work?
Lentiviral vector containing the human Wiskott Aldrich syndrome protein gene is a medicinal product that uses a virus to carry the normal gene necessary for the production of the Wiskott Aldrich protein. A virus is a small organism capable of introducing genetic material into the cells. The type of virus (lentivirus) used in this medicinal product is modified in order to avoid causing any disease in humans. By replacing the abnormal gene, this product is expected to produce the Wiskott Aldrich protein and thus improve the symptoms of the patients.
- What is the stage of development of this medicine?
The effects of lentiviral vector containing the human Wiskott Aldrich syndrome protein gene were evaluated in experimental models.
At the time of submission of the application for orphan designation, no clinical trials in patients with Wiskott Aldrich syndrome condition were initiated.
Lentiviral vector containing the human Wiskott Aldrich syndrome protein gene was not authorised anywhere worldwide for Wiskott Aldrich syndrome or designated as orphan medicinal product elsewhere for this condition, at the time of submission.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 7 December 2005 recommending the granting of this designation.
- Opinions on orphan medicinal product designations are based on the following three criteria:
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- and either the rarity of the condition (affecting not more than five in 10,000 people in the Community) or the insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of the quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/05/345: Public summary of positive opinion for orphan designation of lentiviral vector containing the human Wiskott Aldrich syndrome protein gene for the treatment of Wiskott Aldrich syndrome||(English only)||24/04/2009||19/06/2014|
|Active substance||Lentiviral vector containing the human Wiskott Aldrich Syndrome Protein gene|
|Disease/condition||Treatment of Wiskott Aldrich syndrome|
|Date of decision||24/01/2006|
|Orphan decision number||EU/3/05/345|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor’s contact details:
1 bis rue de l’Internationale
Tel. +33 1 69 47 29 17
Fax +33 1 69 47 19 46
Patients’ associations contact points:
International Patient Organisation for Primary Immunodeficiencies
Main Road, Downderry
Cornwall PL11 3LE
Telephone: + 44 1503 250 668
Telefax: + 44 1503 250 668
Immuno-déficience héréditaire : Recherche, Information, Soutien
55102 Verdun Cedex
Telephone: + 33 3 29 83 48 34
Telefax: + 33 3 29 83 48 35
Deutsche Selbsthilfe angeborene Immundefekte e. V.
Telephone: + 49 8074 8164
Telefax: + 49 8074 973